{"title":"答复\"恩替卡韦治疗停止后 HBsAg 消失的预测\"","authors":"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen","doi":"10.1016/j.jhep.2024.10.041","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>AUTHOR CONTRIBUTIONS</h2>RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.</section></section><section><section><h2>DISCLOSURES/ CONFLICT OF INTEREST STATEMENT</h2>MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.</section></section><section><section><h2>DATA AVAILABILITY STATEMENT</h2>The data from this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Funding</h2>Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"61 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reply to: “Prediction of HBsAg loss after cessation of entecavir therapy”\",\"authors\":\"Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen\",\"doi\":\"10.1016/j.jhep.2024.10.041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<h2>Section snippets</h2><section><section><h2>AUTHOR CONTRIBUTIONS</h2>RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.</section></section><section><section><h2>DISCLOSURES/ CONFLICT OF INTEREST STATEMENT</h2>MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.</section></section><section><section><h2>DATA AVAILABILITY STATEMENT</h2>The data from this study is available from the corresponding author upon reasonable request.</section></section><section><section><h2>Funding</h2>Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.</section></section>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":\"61 1\",\"pages\":\"\"},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.10.041\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.10.041","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
Reply to: “Prediction of HBsAg loss after cessation of entecavir therapy”
Section snippets
AUTHOR CONTRIBUTIONS
RWH Hui was involved in manuscript design and drafting of manuscript. LY Mak was involved in critical revision of manuscript. MF Yuen was involved in critical revision of manuscript and overall study supervision. The authors declare that they have participated in the preparation of the manuscript and have seen and approved the final version.
DISCLOSURES/ CONFLICT OF INTEREST STATEMENT
MF Yuen is an advisory board member and/or received research funding from AbbVie, Arbutus Biopharma, Assembly Biosciences, Bristol Myer Squibb, Dicerna Pharmaceuticals, GlaxoSmithKline, Gilead Sciences, Janssen, Merck Sharp and Dohme, Clear B Therapeutics, Springbank Pharmaceuticals; and received research funding from Arrowhead Pharmaceuticals, Fujirebio Incorporation and Sysmex Corporation. The remaining authors have no conflict of interests.
DATA AVAILABILITY STATEMENT
The data from this study is available from the corresponding author upon reasonable request.
Funding
Innovative Research Fund of the State Key Laboratory of Liver Research, The University of Hong Kong (ref. no.: SKLLR/IRF/2018/07) and the S. K. Yee Medical Foundation Grant (ref. no.: 2141213). The funders had no involvement in study design, data collection/ analysis/ interpretation, writing of the manuscript or decision to submit the article for publication.
期刊介绍:
The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.